SINOPHARM GROUP CO. LTD. Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 16,26 HKD | -1,09% |
|
-7,61% | -20,49% |
| 28/08 | Voorzitter en president van Shyndec Pharmaceutical nemen ontslag | MT |
| 27/08 | Sinopharm Group Co. Ltd. Kondigt een nieuwe voorzitter aan | CI |
Voorlopige winst- en verliesrekening: Sinopharm Group Co. Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 425.273 | 456.415 | 521.051 | 552.148 | 596.570 | 610.066 | 664.913 | 717.826 |
| Variatie | - | 7,32% | 14,16% | 5,97% | 8,05% | 2,26% | 8,99% | 7,96% |
| EBITDA 1 | 17.950 | 19.667 | 23.634 | 24.769 | 24.639 | 23.884 | 26.217 | 28.159 |
| Variatie | - | 9,57% | 20,17% | 4,8% | -0,53% | -3,07% | 9,77% | 7,41% |
| Bedrijfsresultaat (EBIT) 1 | 16.137 | 17.760 | 19.712 | 20.604 | 20.209 | 20.493 | 23.006 | 25.010 |
| Variatie | - | 10,06% | 10,99% | 4,53% | -1,92% | 1,4% | 12,26% | 8,71% |
| Betaalde rente 1 | -3.143 | -2.947 | -3.403 | -3.509 | -2.430 | -2.532 | -2.594 | -2.657 |
| Resultaat voor belastingen (EBT) 1 | 13.760 | 15.598 | 17.003 | 18.564 | 19.512 | 18.540 | 21.003 | 22.738 |
| Variatie | - | 13,36% | 9,01% | 9,18% | 5,11% | -4,98% | 13,29% | 8,26% |
| Nettowinst (verlies) 1 | 6.253 | 7.187 | 7.759 | 8.526 | 9.054 | 8.675 | 9.750 | 10.580 |
| Variatie | - | 14,95% | 7,95% | 9,89% | 6,19% | -4,19% | 12,4% | 8,51% |
| Datum van publicatie | 30/03/20 | 21/03/21 | 20/03/22 | 26/03/23 | 24/03/24 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Balansprognose: Sinopharm Group Co. Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuld 1 | 15.947 | 13.699 | 20.041 | 9.526 | 13.343 | -16.483 | -28.570 | -11.794 |
| Variatie | - | -14,1% | 46,3% | -52,47% | 40,07% | -223,53% | -273,33% | -141,28% |
| Datum van publicatie | 30/03/20 | 21/03/21 | 20/03/22 | 26/03/23 | 24/03/24 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Verwachte kasstroom: Sinopharm Group Co. Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 4.868 | 4.585 | 2.807 | 2.482 | 2.488 | 2.743 | 2.871 | 2.970 |
| Variatie | - | -5,81% | -38,78% | -11,57% | 0,24% | 10,23% | 4,67% | 3,45% |
| Vrije kasstroom (FCF) 1 | 13.909 | -4.574 | 6.501 | 18.481 | 14.685 | 21.665 | 11.660 | 10.474 |
| Variatie | - | -132,89% | -242,12% | 184,29% | -20,54% | 47,54% | -46,18% | -10,17% |
| Datum van publicatie | 30/03/20 | 21/03/21 | 20/03/22 | 26/03/23 | 24/03/24 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Verwachte financiële ratio's: Sinopharm Group Co. Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
| EBITDA-marge (%) | 4,22% | 4,31% | 4,54% | 4,49% | 4,13% | 3,92% | 3,94% | 3,92% |
| EBIT-marge (%) | 3,79% | 3,89% | 3,78% | 3,73% | 3,39% | 3,36% | 3,46% | 3,48% |
| EBT-marge (%) | 3,24% | 3,42% | 3,26% | 3,36% | 3,27% | 3,04% | 3,16% | 3,17% |
| Nettomarge (%) | 1,47% | 1,57% | 1,49% | 1,54% | 1,52% | 1,42% | 1,47% | 1,47% |
| FCF-marge (%) | 3,27% | -1% | 1,25% | 3,35% | 2,46% | 3,55% | 1,75% | 1,46% |
| Vrije kasstroom/nettoresultaat (%) | 222,46% | -63,64% | 83,79% | 216,77% | 162,19% | 249,75% | 119,59% | 99% |
Winstgevendheid | ||||||||
| ROA | 2,47% | 2,47% | 2,4% | 2,44% | 2,42% | 2,14% | 2,22% | 2,24% |
| ROE | 13,86% | 13,85% | 13,12% | 13,12% | 12,69% | 10,65% | 10,95% | 10,83% |
Financiële gezondheid | ||||||||
| Hefboom (schuld/ebitda) | 0,89x | 0,7x | 0,85x | 0,38x | 0,54x | - | - | - |
| Schuld/vrije kasstroom | 1,15x | -3x | 3,08x | 0,52x | 0,91x | - | - | - |
Kapitaalintensiteit | ||||||||
| Kapitaaluitgaven/omzet (%) | 1,14% | 1% | 0,54% | 0,45% | 0,42% | 0,45% | 0,43% | 0,41% |
| CAPEX / EBITDA (%) | 27,12% | 23,31% | 11,88% | 10,02% | 10,1% | 11,48% | 10,95% | 10,55% |
| CAPEX / FCF (%) | 35% | -100,24% | 43,18% | 13,43% | 16,95% | 12,66% | 24,62% | 28,36% |
Bestanddelen per aandeel | ||||||||
| Kasstroom per aandeel 1 | 6,319 | 3,585 | 2,983 | 6,718 | 5,503 | 7,034 | 5,337 | 5,256 |
| Variatie | - | -43,26% | -16,81% | 125,23% | -18,08% | 27,82% | -24,12% | -1,53% |
| Dividend per aandeel 1 | 0,6 | 0,69 | 0,75 | 0,82 | 0,87 | 0,8559 | 0,932 | 0,9851 |
| Variatie | - | 15% | 8,7% | 9,33% | 6,1% | -1,62% | 8,89% | 5,7% |
| Nettoactief per aandeel 1 | 15,97 | 18,12 | 19,83 | 21,81 | 23,9 | 26,16 | 28,87 | 31,85 |
| Variatie | - | 13,44% | 9,47% | 9,99% | 9,57% | 9,47% | 10,37% | 10,3% |
| WPA 1 | 2,1 | 2,31 | 2,49 | 2,73 | 2,9 | 2,774 | 3,124 | 3,397 |
| Variatie | - | 10% | 7,79% | 9,64% | 6,23% | -4,35% | 12,63% | 8,73% |
| Aantal aandelen (in duizend) | 2.967.629 | 3.118.654 | 3.120.656 | 3.120.656 | 3.120.656 | 3.120.656 | 3.120.656 | 3.120.656 |
| Datum van publicatie | 30/03/20 | 21/03/21 | 20/03/22 | 26/03/23 | 24/03/24 | - | - | - |
1CNY
Geschatte gegevens
| 2024 * | 2025 * | |
|---|---|---|
| K/w-verhouding | 5,35x | 4,75x |
| PBR-ratio | 0,57x | 0,51x |
| EV/omzet | 0,05x | 0,03x |
| Dividendrendement | 5,76% | 6,28% |
Meer waarderingsratio's
* Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Trading rating
Beleggingsrating
ESG Refinitiv
C
Verkoop
Koop
Gemiddeld advies
Kopen
Aantal analisten
17
Laatste slotkoers
14,85CNY
Gemiddelde koersdoel
22,12CNY
Spread / Gemiddelde doel
+48,96%
Kwartaalomzet - Afwijkingspercentage
- Beurs
- Aandelen
- Koers 1099
- Financiën Sinopharm Group Co. Ltd.
